Therapy Areas: Oncology
Bristol-Myers Squibb Partners with Illumina to Develop Diagnostic Oncology Assay to Measure Predictive Genomic Biomarkers
18 April 2018 - - A collaboration between New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) and San Diego, California-based DNA sequencing and array-based technologies specialist Illumina, Inc. (NASDAQ: ILMN) will utilize Illumina's next-generation sequencing technology to develop and globally commercialize in-vitro diagnostic assays in support of Bristol-Myers Squibb's oncology portfolio, the companies said.
The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive genomic biomarkers, including tumor mutation burden (TMB).
Illumina's TruSight Oncology 500 assay is being developed to detect most of the known biomarkers for oncology therapeutics, including TMB and microsatellite instability for immunotherapies.
Cancer immunotherapy works by helping the immune system mount an anti-cancer response, a process that depends in part on the recognition of cancer-specific proteins called neoantigens.
Bristol-Myers Squibb's clinical development program includes 24 clinical-stage molecules designed to target different immune system pathways across more than 50 types of cancers, and through its translational capabilities, has identified a number of potentially predictive biomarkers, including PD-L1, TMB, MSI-H/dMMR and LAG-3.
Bristol-Myers Squibb's mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Illumina serves customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Login
Username:

Password: